Incysus Therapeutics, Inc.
Incysus Therapeutics, Inc. is listed today as IN8Bio, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2025 | $20 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Oct 2024 | $12 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Dec 2023 | $14 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| May 2018 | $35 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Incysus Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2025).
SEC Form D · Dec 2025
The industry group it chose in its notices: Biotechnology.
SEC Form D · Dec 2025
That is all the official record says: Incysus Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Incysus Therapeutics, Inc. are on record.
Investors#
14 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| BIOS Advisors GP, LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| BIOS Capital Management, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| BIOS Equity Partners III, LP | Private equity | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Bios Equity Partners II, LP | Private equity | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| BIOS Fund III, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| BIOS Fund III NT, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| BIOS Fund III QP, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| BIOS Fund II, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| BIOS Fund II NT, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| BIOS Fund II QP, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| BIOS Incysus Co-Invest I, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cavu Advisors, LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cavu Management, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Transcend Partners Opportunity Fund LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 33 investors.
Largest shareholders today
Institutions holding IN8Bio, Inc. shares, as of Sep 30, 2026.
- Alyeska Investment Group, L.P.$1 M8.74%
- Franklin Templeton Inc$1 M8.46%
- 683 Capital Management, LLC$1 M6.70%
- Stonepine Capital Management, LLC$1 M6.46%
- Vanguard Capital Management LLC$0 M0.82%
- BIOS Capital Management, LP$0 M0.75%
- Geode Capital Management, LLC$0 M0.58%
- Vanguard Fiduciary Trust Co$0 M0.40%
- UBS Group AG$0 M0.34%
- Renaissance Technologies LLC$0 M0.31%
- Texas Capital Bank Wealth Management Services Inc$0 M0.22%
- Citadel Advisors LLC$0 M0.21%
- Northern Trust Corp$0 M0.20%
- Squarepoint Ops LLC$0 M0.10%
- Northwestern Mutual Wealth Management Co$0 M0.03%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Kate R. Rochlin | Executive officer | Dec 2025 |
| Lawrence R. Lamb | Executive officer | Dec 2025 |
| Patrick McCall | Executive officer | Dec 2025 |
| William Ho | Executive officer | Dec 2025 |
| Trishna R. Goswami | Executive officer | Dec 2023 |
| Larry Lamb | Executive officer | Sep 2020 |
| Melissa Beelen | Executive officer | Sep 2020 |
| Alan S. Roemer | Director | Dec 2025 |
| Corinne R. Epperly | Director | Dec 2025 |
| Emily R. Fairbairn | Director | Dec 2025 |
| Jeremy R. Graff | Director | Dec 2025 |
| Luba R. Greenwood | Director | Dec 2025 |
| Peter S. Brandt | Director | Dec 2025 |
| William Ho | Director | Dec 2025 |
| Travis R. Whitfill | Director | Oct 2024 |
| Emily S. Fairbairn | Director | Dec 2023 |
| Peter Brandt | Director | Sep 2020 |
| Thomas Cirrito | Director | Sep 2020 |
| Travis Whitfill | Director | Sep 2020 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.